In March 2025, Zacks Equity Research upgraded Vicarious Surgical (RBOT) to a Zacks Rank #2 (Buy).
The upgrade was attributed to an upward trend in the company's earnings estimates.
Zacks cited an expected EPS of -$7.15 for fiscal year 2025, representing a 33.5% improvement year-over-year, as a key factor in the positive re-evaluation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.